334.13
-14.6(-4.19%)
Currency In USD
| Previous Close | 348.73 |
| Open | 350 |
| Day High | 350.19 |
| Day Low | 330.37 |
| 52-Week High | 377.46 |
| 52-Week Low | 200.63 |
| Volume | 321,624 |
| Average Volume | 326,388 |
| Market Cap | 7.42B |
| PE | -17.47 |
| EPS | -19.13 |
| Moving Average 50 Days | 290.86 |
| Moving Average 200 Days | 300 |
| Change | -14.6 |
If you invested $1000 in Madrigal Pharmaceuticals, Inc. (MDGL) 10 years ago, it would be worth $4,419.71 as of July 18, 2025 at a share price of $334.13. Whereas If you bought $1000 worth of Madrigal Pharmaceuticals, Inc. (MDGL) shares 5 years ago, it would be worth $3,047.24 as of July 18, 2025 at a share price of $334.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
GlobeNewswire Inc.
Jul 16, 2025 12:00 PM GMT
• Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics f
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
GlobeNewswire Inc.
Jun 20, 2025 10:30 AM GMT
Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected in August 2025; if approved, resmetirom will be the first medication for peopl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jun 17, 2025 8:05 PM GMT
CONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced tha